Previous Education and Employment
2004 - present: Associate Professor of Pharmacology at the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Czech Republic
1993-2004: Researcher, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Czech Republic
1992: Ph.D. in Pharmaceutical Sciences, Institute of Experimental Biopharmacy, Czechoslovak Academy of Sciences, Czech Republic
1984-1992: Researcher, Institute of Experimental Biopharmacy, Czechoslovak Academy of Sciences, Czech Republic
1984: PharmDr., Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic
1979-1984: Masters study, Faculty of Pharmacy, Charles University (M.Sc. in ClinicalPharmacology)
Research Interests
- Study on pharmacokinetics, in vivo studies, analysis of elimination and transport mechanisms at the cellular and organ level including chiral aspects
- Preclinical development of new radiopharmaceuticals
- Preclinical study on drug toxicity
- Author of 2 final reports of preclinical and 2 final reports of clinical investigations
- Participation in 11 research projects and grants
Teaching
Lecturer for pregradual and postgradual students in pharmacology and radiopharmacy at the Faculty of Pharmacy, Charles University in Prague.
Co-author of 2 university textbooks.
Supervisor of diploma thesis and Ph.D. students at the Department of Pharmacology and Toxicology.
Mentor of postdoc students.
Professional Memberships
European Society of Biochemical Pharmacology (ESBP)
Czech Society for Experimental and Clinical Pharmacology and Toxicology
Grants Received
Study on relationships between toxicity and transport mechanism of antivirals, IGA MZ, No. NT12398 (2011-2014)
Increasing of the R&D capacity at Charles University through new positions for graduates of doctoral studies, Operational programme of EU, No. CZ.1.07/2.3.00/30.0061 (2012 – 2015)
Supporting of establishment, development and mobility of quality research teams at the Charles University Operational programme of EU, No. CZ.1.07/2.3.00/30.0022 (2012 – 2014)
In vitro study on mechanisms or renal membrane transport of antivirals using cellular models, GAUK 360811 (2011-2013)
Study of receptor-specific peptides in thje kidney in vitro, GAUK, No. 376411 (2011-2013)
Possibility of modification of nephrotoxicity of radiopharmaceuticals from the group of somatostatin analogs, IGAMZ, No. NR9208 (2007-2009)
Publications
based on WoS (January 2016)
Author/co-author of 49 research articles, 1 review article
279 citations (without self-citations)
H-index = 11 (without self-citations)
Selected publications:
Macáková K, Mladěnka P, Filipský T, Říha M, Jahodář L, Trejtnar F, Bovicelli P, Proietti Silvestri I, Hrdina R, Saso L. Iron reduction potentiates hydroxyl radical formation only in flavonols. Food Chem. 2012;135(4):2584-92.
Kozic J, Novotná E, Volková M, Stolaříková J, Trejtnar F, Wsól V, Vinšová J. Synthesis and in vitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2'-hydroxybenzanilides, their thioxo analogues and benzoxazoles. Eur J Med Chem. 2012; 56:108-19.
Kozic J, Novotná E, Volková M, Stolaříková J, Trejtnar F, Vinšová J. Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues. Eur J Med Chem. 2012;56:387-95.
Krátký M, Vinšová J, Novotná E, Mandíková J, Wsól V, Trejtnar F, Ulmann V, Stolaříková J, Fernandes S, Bhat S, Liu JO. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis (Edinb). 2012;92(5):434-9.
Nováková L, Gottvald T, Vlčková H, Trejtnar F, Mandíková J, Solich P. Highly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography-ultra-high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2012;1259:237-43.
Novy Z, Barta P, Mandikova J, Laznicek M, Trejtnar F. A comparison of in vitro methods for determining the membrane receptor expression in cell lines. Nucl Med Biol. 2012;39(7):893-6.
Trejtnar F, Laznickova A, Laznicek M, Novy Z, Maina T, Nock BA, Behe M. Distribution, elimination, and renal handling of (99m)technetium-Demogastrin 1. Cancer Biother Radiopharm. 2012;27(2):169-74.
Krátký M, Vinšová J, Volková M, Buchta V, Trejtnar F, Stolaříková J. Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold. Eur J Med Chem. 2012;50:433-40.
Laznickova A, Laznicek M, Trejtnar F, Maecke HR, Eisenwiener KP, Reubi JC. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats. Anticancer Res. 2010;30(6):2177-84.
Trejtnar F, Novy Z, Petrik M, Laznickova A, Melicharova L, Vankova M, Laznicek M. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111. Ann Nucl Med. 2008;22(10):859-67.
Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008;36(2):339-48.
Trejtnar F, Laznicek M, Laznickova A, Kopecky M, Petrik M, Béhé M, Schmidt J, Maecke H, Maina T, Nock B. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer Res. 2007;27(2):907-12.
Kopecky M, Trejtnar F, Laznicek M, Laznickova A, Semecky V, Maina T, Nock B. 99mTc demotate 1: biodistribution and elimination characteristics in rats. Nucl Med Commun. 2005;26(6):549-54.
Kopecky M, Semecky V, Trejtnar F, Laznicek M, Laznickova A, Nachtigal P, Decristoforo C, Mather SJ, Mäcke HR. Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. Nucl Med Biol. 2004;31(2):231-9.
Trejtnar F, Král R, Pávek P, Wsól V. Stereoselective pharmacokinetics and metabolism of flobufen in guinea pigs. Chirality. 2003;15(8):724-9.
Trejtnar F, Laznicek M, Laznickova A. Comparison of 99mTc-mercaptoacetyltriglycine and [131I]-o-iodohippurate elimination in perfused rat kidney. Nucl Med Biol. 2003;30(1):45-9.
Laznicek M, Laznickova A, Trejtnar F, Lorenc P, Varvarigou A, Bouziotis P, Archimandritis S. Lanreotide labeled with 99mTc: preparation, preclinical testing and comparison with (111)In-DTPA-octreotide. Anticancer Res. 2002;22(4):2125-30.
Trejtnar F, Laznicek M. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med. 2002;46(3):181-94.
Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki KH, Akizawa H, Arano Y, Yokoyama A. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats. Eur J Drug Metab Pharmacokinet. 2002;27(1):37-43.
Trejtnar F, Laznicek M, Laznickova A, Mather SJ. Pharmacokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med. 2000;41(1):177-82.
Trejtnar F, Wsol V, Szotakova B, Skalova L, Pavek P, Kuchar M. Stereoselective pharmacokinetics of flobufen in rats. Chirality. 1999;11(10):781-6.